Andreas Tiede

List of Publications by Citations

131 papers	3,382 citations	30 h-index	55 g-index
153 ext. papers	4,085 ext. citations	4.6 avg, IF	5.47 L-index

#	Paper	IF	Citations
131	How I treat the acquired von Willebrand syndrome. *Blood*, **2011**, 117, 6777-85	2.2	239
130	Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. *Blood*, **2011**, 118, 2695-701	2.2	166
129	Acquired hemophilia A: Updated review of evidence and treatment guidance. *American Journal of Hematology*, **2017**, 92, 695-705	7.1	162
128	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. *Blood*, **2012**, 120, 2405-11	2.2	135
127	Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. *Blood*, **2015**, 125, 1091-7	2.2	133
126	Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. *Journal of Thrombosis and Haemostasis*, **2008**, 6, 569-76	15.4	126
125	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 670-8	15.4	124
124	Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. *Blood*, **2013**, 121, 1039-48	2.2	122
123	Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes. *Biological Chemistry*, **1999**, 380, 503-23	4.5	97
122	Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 191-201	5.3	95
121	Pigs transgenic for human thrombomodulin have elevated production of activated protein C. *Xenotransplantation*, **2009**, 16, 486-95	2.8	88
120	Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys. *Xenotransplantation*, **2011**, 18, 355-68	2.8	75
119	Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. *Blood*, **2015**, 125, 1180-8	2.2	74
118	International recommendations on the diagnosis and treatment of acquired hemophilia A. *Haematologica*, **2020**, 105, 1791-1801	6.6	71
117	Results from a large multinational clinical trial (guardian 1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. *Haemophilia*, **2013**, 19, 691-7	3.3	70
116	Prothrombotic immune thrombocytopenia after COVID-19 vaccination. *Blood*, **2021**, 138, 350-353	2.2	69
115	Diagnosis and treatment of acquired von Willebrand syndrome. *Thrombosis Research*, **2012**, 130 Suppl 2, S2-6	8.2	61

114	Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, 803-11	5.3	58
113	Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). *Annals of Hematology*, **2014**, 93, 1953-63	3	56
112	Half-life extended factor VIII for the treatment of hemophilia A. *Journal of Thrombosis and Haemostasis*, **2015**, 13 Suppl 1, S176-9	15.4	55
111	Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. *Annals of Hematology*, **2010**, 89, 309-16	3	47
110	Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32). *Annals of the Rheumatic Diseases*, **2008**, 67, 154-61	2.4	45
109	Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. *Haemophilia*, **2011**, 17, 854-9	3.3	43
108	A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. *American Journal of Transplantation*, **2014**, 14, 2577-87	8.7	40
107	Recovery and composition of microparticles after snap-freezing depends on thawing temperature. *Blood Coagulation and Fibrinolysis*, **2009**, 20, 52-6	1	40
106	Legionnaires' disease in immunocompromised patients: a case report of Legionella longbeachae pneumonia and review of the literature. *Journal of Medical Microbiology*, **2008**, 57, 384-387	3.2	40
105	Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. *Gene Therapy*, **2003**, 10, 1917-25	4	34
104	Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 940-7	15.4	34
103	Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. *Blood*, **2016**, 127, 2289-97	2.2	33
102	PK-guided personalized prophylaxis with Nuwiq (human-cl rhFVIII) in adults with severe haemophilia A. *Haemophilia*, **2017**, 23, 697-704	3.3	30
101	Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. *Thrombosis and Haemostasis*, **2008**, 99, 616-22	7	30
100	Human and mouse Gpi1p homologues restore glycosylphosphatidylinositol membrane anchor biosynthesis in yeast mutants. *Biochemical Journal*, **1998**, 334 (Pt 3), 609-16	3.8	30
99	Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. *Blood Reviews*, **2016**, 30, 35-48	11.1	28
98	The first recombinant FVIII produced in human cells--an update on its clinical development programme. *Haemophilia*, **2014**, 20 Suppl 1, 1-9	3.3	28
97	Isotype controls in phenotyping and quantification of microparticles: a major source of error and how to evade it. *Thrombosis Research*, **2008**, 122, 691-700	8.2	28

96	Management of acquired haemophilia A. *Hamostaseologie*, **2015**, 35, 311-8	1.9	27
95	Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). *Annals of Hematology*, **2016**, 95, 707-18	3	26
94	Prophylaxis vs. on-demand treatment with Nuwiq( ) (Human-cl rhFVIII) in adults with severe haemophilia A. *Haemophilia*, **2016**, 22, 374-80	3.3	26
93	Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. *Haemophilia*, **2008**, 14, 736-42	3.3	25
92	Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 36-43	15.4	24
91	Characterisation of the enzymatic complex for the first step in glycosylphosphatidylinositol biosynthesis. *International Journal of Biochemistry and Cell Biology*, **2000**, 32, 339-50	5.6	23
90	Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. *JAMA Neurology*, **2021**, 78, 1314-1323	17.2	23
89	siRNA mediated knockdown of tissue factor expression in pigs for xenotransplantation. *American Journal of Transplantation*, **2015**, 15, 1407-14	8.7	22
88	Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials. *Haemophilia*, **2017**, 23, 547-555	3.3	21
87	Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. *Annals of Hematology*, **2009**, 88, 365-70	3	21
86	Acquired haemophilia caused by non-haemophilic factor VIII gene variants. *Annals of Hematology*, **2010**, 89, 607-12	3	20
85	Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. *Xenotransplantation*, **2008**, 15, 46-55	2.8	20
84	Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia. *Annals of Hematology*, **2018**, 97, 1889-1901	3	20
83	Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. *Blood*, **2017**, 130, 808-816	2.2	18
82	Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. *Annals of Hematology*, **2019**, 98, 2035-2044	3	18
81	The use of recombinant activated factor VII in patients with acquired haemophilia. *Blood Reviews*, **2015**, 29 Suppl 1, S19-25	11.1	18
80	Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study. *Blood*, **2020**, 136, 279-287	2.2	16
79	CD8beta/CD28 expression defines functionally distinct populations of peripheral blood T lymphocytes. *Clinical and Experimental Immunology*, **2003**, 133, 334-43	6.2	16

78	Glycosylphosphatidylinositol (GPI)-deficient Jurkat T cells as a model to study functions of GPI-anchored proteins. *Clinical and Experimental Immunology*, **2000**, 122, 49-54	6.2	15
77	Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. *Annals of Hematology*, **2017**, 96, 1253-1270	3	14
76	Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa). *Journal of Thrombosis and Haemostasis*, **2011**, 9, 1191-9	15.4	14
75	On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. *Haemophilia*, **2012**, 18, 255-62	3.3	13
74	Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 193-4	15.4	13
73	Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement. *Haemophilia*, **2019**, 25, 969-978	3.3	12
72	Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia. *Hamostaseologie*, **2017** , 37, 307-310	1.9	12
71	PF4-Dependent Immunoassays in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: Results of an Interlaboratory Comparison. *Thrombosis and Haemostasis*, **2021**, 121, 1622-1627	7	12
70	Should emicizumab be used in patients with acquired hemophilia A?. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 637-644	15.4	12
69	Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. *Haemophilia*, **2018**, 24, e391-e394	3.3	12
68	Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation. *Vox Sanguinis*, **2013**, 105, 18-27	3.1	11
67	Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure. *Critical Care*, **2021**, 24, 701	10.8	11
66	Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. *Annals of Hematology*, **2020**, 99, 2689-2698	3	11
65	Ovine blood: establishment of a list of reference values relevant for blood coagulation in sheep. *ASAIO Journal*, **2012**, 58, 79-82	3.6	10
64	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2145-2154	15.4	9
63	DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders. *Laboratory Animals*, **2009**, 43, 390-3	2.6	9
62	Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation. *Xenotransplantation*, **2016**, 23, 117-27	2.8	9
61	Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014. *Haemophilia*, **2015**, 21 Suppl 1, 1-12	3.3	8

60	Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH). *Haemophilia*, **2017**, 23, 721-727	3.3	8
59	Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 779-93	5.3	8
58	Effect of TNF-alpha blockade on coagulopathy and endothelial cell activation in xenoperfused porcine kidneys. *Xenotransplantation*, **2015**, 22, 284-94	2.8	7
57	Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results. *Hamostaseologie*, **2015**, 35, 364-71	1.9	7
56	Body Mass Index Best Predicts Recovery of Recombinant Factor VIII in Underweight to Obese Patients with Severe Haemophilia A. *Thrombosis and Haemostasis*, **2020**, 120, 277-288	7	7
55	Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy. *Current Medical Research and Opinion*, **2020**, 36, 9-15	2.5	7
54	CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro. *Thrombosis and Haemostasis*, **2017**, 117, 1679-1687	7	6
53	Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. *Thrombosis and Haemostasis*, **2015**, 114, 1127-35	7	6
52	Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin. *Haemophilia*, **2013**, 19, 236-41	3.3	6
51	Interim results from a large multinational extension trial (guardian 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. *Haemophilia*, **2016**, 22, e445-9	3.3	6
50	Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model. *Haematologica*, **2021**, 106, 1902-1909	6.6	5
49	Recombinant human antithrombin prevents xenogenic activation of hemostasis in a model of pig-to-human kidney transplantation. *Xenotransplantation*, **2014**, 21, 367-75	2.8	5
48	The human GPI1 gene is required for efficient glycosylphosphatidylinositol biosynthesis. *Gene*, **2001**, 271, 247-54	3.8	5
47	The rising incidence of acquired haemophilia A in Germany. *Haemophilia*, **2021**, 27, e466-e468	3.3	5
46	Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice. *Blood*, **2021**, 137, 1072-1081	2.2	5
45	SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A. *Haemophilia*, **2020**, 26, 47-55	3.3	4
44	Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study. *Annals of Hematology*, **2020**, 99, 2105-2112	3	4
43	Successful immune tolerance induction using turoctocog alfa in an adult haemophilia A patient. *Blood Coagulation and Fibrinolysis*, **2017**, 28, 181-184	1	3

42	Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in Vitro. *Scandinavian Journal of Immunology*, **2017**, 86, 91-99	3.4	3
41	Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary. *Haemophilia*, **2020**, 26, 999-1008	3.3	3
40	Measurements of endogenous thrombin potential using the CAT method in cats: Reference values and influence of the direct factor Xa inhibitor apixaban. *Research in Veterinary Science*, **2019**, 127, 113-121	2.5	3
39	Expression of human thrombomodulin on porcine endothelial cells can reduce platelet aggregation but did not reduce activation of complement or endothelium - an experimental study. *Transplant International*, **2020**, 33, 437-449	3	3
38	Acquired bleeding disorders. *Haemophilia*, **2021**, 27 Suppl 3, 5-13	3.3	3
37	Trend In Hospital Cases of Acquired Hemophilia A (AHA) 2010-2015 In Germany. *Value in Health*, **2017**, 20, A566	3.3	2
36	CD8alpha+beta(low) effector T cells in systemic lupus erythematosus. *Scandinavian Journal of Immunology*, **2008**, 67, 501-8	3.4	2
35	Critical Bleeding in Acquired Hemophilia A: Bypassing Agents or Recombinant Porcine Factor VIII?. *Hamostaseologie*, **2021**, 41, 240-245	1.9	2
34	Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia. *Hamostaseologie*, **2021**, 41, 190-196	1.9	2
33	Investigation of the influence of xenoreactive antibodies on activation of complement and coagulation in an ex vivo perfusion animal study using porcine kidneys. *Transplant International*, **2019**, 32, 546-556	3	2
32	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 973-973	5.3	1
31	Activated Clotting Time (ACT) for Monitoring of Low-Dose Heparin: Performance Characteristics in Healthy Adults and Critically Ill Patients. *Clinical and Applied Thrombosis/Hemostasis*, **2020**, 26, 1076029620975494	3.3	1
30	Acquired Hemophilia Caused by Non-Hemophilic Factor VIII Gene Variants.. *Blood*, **2004**, 104, 3083-3083	2.2	1
29	Deletion or Inhibition of Fc Gamma Receptor IIb (CD32) Prevents the Memory B Cell Response to Factor VIII in a Hemophilia A Mouse Model. *Blood*, **2011**, 118, 204-204	2.2	1
28	Personalized Prophylaxis with Human-Cl Recombinant FVIII in HA Patients. *Blood*, **2015**, 126, 547-547	2.2	1
27	Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B. *PLoS Genetics*, **2020**, 16, e1008690	6	1
26	International consensus recommendations on the management of people with haemophilia B.. *Therapeutic Advances in Hematology*, **2022**, 13, 20406207221085202	5.7	1
25	Vaccine-Induced Thrombocytopenia and Thrombosis (VITT) Antibodies Recognize Neutrophil-Activating Peptide 2 (NAP2) As Well As Platelet Factor 4 (PF4): Mechanistic and Clinical Implications. *Blood*, **2021**, 138, 292-292	2.2	0

24	The Art of Detecting Antibodies against Factor VIII. *Hamostaseologie*, **2020**, 40, 485-490	1.9	0
23	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. *Blood Advances*, **2021**, 5, 2987-3001	7.8	0
22	Acquired bleeding disorders.. *Haemophilia*, **2022**, 28 Suppl 4, 68-76	3.3	0
21	Addition of in-vitro generated endothelial microparticles to von-Willebrand plasma improves primary and secondary hemostasis. *Thrombosis Research*, **2014**, 133, 445-50	8.2	
20	Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A. *Blood*, **2020**, 136, 24-25	2.2	
19	Recombinant Factor VIIa for Major Surgery in Severe Factor XI Deficiency: Pharmacodynamic Monitoring Using Thromboelastometry **2007**, 133-136		
18	Update of the Inhibitor-Immunology-Study **2007**, 34-39		
17	Thromboelastometry in Patients Receiving Platelet Transfusion after Chemotherapy.. *Blood*, **2004**, 104, 3630-3630	2.2	
16	Platelet-Derived Microparticles Accelerate Engraftment of Peripheral Blood Stem Cells in Human Allogeneic Transplantation.. *Blood*, **2005**, 106, 3035-3035	2.2	
15	Diagnostic Workup of Patients with Acquired Von Willebrand Syndrome.. *Blood*, **2006**, 108, 1045-1045	2.2	
14	An Ex Vivo Perfusion Model To Study the Treatment of Thrombotic Microangiopathy during Pig-to-Human Xenogenic Kidney Transplantation.. *Blood*, **2007**, 110, 3190-3190	2.2	
13	Acquired Glanzmann Thrombasthenia in a Patient with Myelodysplastic Syndrome **2008**, 184-186		
12	A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A. *Blood*, **2018**, 132, 2491-2491	2.2	
11	Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A. *Journal of Blood Medicine*, **2021**, 12, 935-943	2.3	
10	Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.. *Blood*, **2009**, 114, 4443-4443	2.2	
9	Comparison Of Autologous Microparticles and Fucosyltransferase-7 For Adhesion Improvement Of Hematopoietic Stem Cells To Bone Marrow Endothelial Cells In a Microfluidic Flow Chamber. *Blood*, **2013**, 122, 2000-2000	2.2	
8	Lupus anticoagulant in children – a confounding factor in diagnosis and targeted therapy. *Romanian Journal of Laboratory Medicine*, **2021**, 29, 287-298	0.3	
7	Monitoring of different factor VIII replacement products using a factor VIII one-stage clotting assay on cobas t 511/711 analysers. *Haemophilia*, **2021**, 27, e704-e712	3.3	

List of Publications

6 Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B **2020**, 16, e1008690

5 Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B **2020**, 16, e1008690

4 Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B **2020**, 16, e1008690

3 Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B **2020**, 16, e1008690

2 Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B **2020**, 16, e1008690

1 Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B **2020**, 16, e1008690